
Guidelines favor ticagrelor or prasugrel over clopidogrel in patients with myocardial infarction. However, the Popular Genetics trial (Patient Outcome After Primary Percutaneous Coronary Intervention [PCI]) showed that in patients with primary PCI, aCYP2C19genotype–guided strategy was associated with a lower bleeding risk without increasing thrombotic risk, compared with routine ticagrelor/prasugrel treatment...
Like
Save
Share